Genocea Biosciences Inc (GNCAQ)

[jondoeuk]

This year there will be interim data from ten patients, first patient will dosed in the combo trials, they will enrol the first patient in the US, an IND will be filed for HNSCC, and Catapult manufacturing will come on-line.

In the first half of next year the first patient will dosed with higher doses, there will be interim data from the combo trials, they will initiate a tumour archiving program and establish a US R&D facility.

For the second half, more interim data from those given higher doses, they will incorporate closed automation tech and start a trial in the follow-on indication.

As for the gene editing tech (undisclosed), it may be used to prevent the expression of immune checkpoints expressed, add molecules to increase trafficking to tumours, and/or deliver inflammatory mediators into the TME, including but not limited to cytokines, soluble immune-regulatory receptors and/or ligands.